Company: CNTB
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001835268-25-000014
Chunk: 16

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-03-31
Form: 10-K
Item: Item 11
Chunk 16
---
 their continuous service with the Company as of each applicable vesting date. The options granted to Dr. Quart, Mr. Szekeres, and Ms. Peraza are subject to potential accelerated vesting in connection with a qualifying termination of employment or change in control, as described below under the subsection titled “Employment Arrangements with our Current Named Executive Officers.” 

The equity awards granted to our Named Executive Officers during 2024 that remained outstanding at December 31, 2024, are reflected in the Outstanding Equity Awards at Year End table below.

142

Outstanding Equity Awards at Year End

The following table provides information concerning outstanding stock options held by each Named Executive Officer as of December 31, 2024, in respect of ordinary shares:

Option AwardsNumber of Securities Underlying Unexercised OptionsNameExercisable (#)Unexercisable (#) (1)OptionExercise Price($)OptionGrant DateOptionExpiration DateCurrent Executive Officers:Barry D. Quart, Pharm.D.— 2,658,734 $1.77 06/12/202406/12/2034— 432,392 $0.97 12/26/202412/26/2034David Szekeres— 1,772,489 $1.77 06/12/202406/12/2034— 409,355 $0.97 12/26/202412/26/2034Lisa Peraza, CPA— 400,000 $1.15 08/12/202408/12/2034— 55,318 $0.97 12/26/202412/26/2034Former Executive Officers:Zheng Wei, Ph.D.143,678 — $8.16 12/11/202003/31/2025311,171 — $11.69 02/20/202103/31/2025142,552 — $4.12 03/01/202212/31/2025158,125 — $1.27 03/01/202312/31/2025Wubin Pan, Ph.D.143,678 — $8.16 12/11/202003/31/2025311,171 — $11.69 02/20/202103/31/2025121,479 — $4.12 03/01